Prevalence of serum neutralizing antibodies to adenovirus type 5 (Ad5) and 41 (Ad41) in children is associated with age and sanitary conditions.
Neutralizing antibody (NAb) can dampen the immunogenicity of adenovirus (Ad) vector-based vaccine. Vector systems based on human adenovirus type 41 (Ad41) have been constructed and used to develop recombinant vaccines. Here, we attempted to study the seroprevalence of NAbs to Ad5 and Ad41 among children and adults in Qinghai province, China. The positive rates (titer⩾40) of Ad5 and Ad41 NAb in adults from Xining city were 75.7% and 94.7%, respectively. The moderate/high-positive rates (titer⩾160) of NAb were quite close between the two viruses in adults (70.4% for Ad5 and 73.5% for Ad41). Age-dependent increase of NAb seroprevalence was observed for both viruses in children. NAb-positive rate of Ad41 reached 50% at 3.3-4.6years of age for children from Chengxi district, Xining city, approximately 1.5years earlier than that of Ad5 did. Interestingly, NAb level was also associated with sanitary conditions among young children. For Ad5, 8-15% children (0.2-3.0years of age) from city or town, where the sanitations were relatively better, had moderate/high-positive NAb, while the same rate was 62% for children from villages. For Ad41, 22% children from city, 47% from town and 88% from villages possessed moderate/high-positive NAb. The possible influence of NAb titer distributions on the application of Ad41-vectored vaccines was discussed in detail. Our results suggested that children from places with poor sanitations should be included for comprehensive Ad NAb seroprevalence studies, and provided insights to the applications of Ad41 vectors.
Qinghai Center for Disease Control and Prevention, Xining, Qinghai 810007, China.
Wei-Xiong
WX
Yang
State Key Laboratory of Infectious Disease Prevention and Control, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100052, China.
Xiao-Hui
XH
Zou
Qinghai Center for Disease Control and Prevention, Xining, Qinghai 810007, China.
Shuang-Ying
SY
Jiang
Qinghai Center for Disease Control and Prevention, Xining, Qinghai 810007, China.
Nan-Nan
NN
Lu
Qinghai Provincial Kangle Hospital, Xining, Qinghai 810006, China.
Mei
M
Han
Qinghai Center for Disease Control and Prevention, Xining, Qinghai 810007, China.
Jian-Hai
JH
Zhao
State Key Laboratory of Infectious Disease Prevention and Control, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100052, China.
Xiao-Juan
XJ
Guo
Qinghai Center for Disease Control and Prevention, Xining, Qinghai 810007, China. Electronic address: qhzhaoshengcang@163.com.
Sheng-Cang
SC
Zhao
Qinghai Center for Disease Control and Prevention, Xining, Qinghai 810007, China; State Key Laboratory of Infectious Disease Prevention and Control, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100052, China. Electronic address: luzz@ivdc.chinacdc.cn.
Zhuo-Zhuang
ZZ
Lu
D000257:Adenoviridae Infections / Q000453:epidemiology / Q000276:immunology* / Q000821:virology; D062705:Adenovirus Vaccines / Q000276:immunology; D000260:Adenoviruses, Human / Q000276:immunology*; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D057134:Antibodies, Neutralizing / Q000097:blood*; D000914:Antibodies, Viral / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D002681:China / Q000453:epidemiology; D005260:Female; D005822:Genetic Vectors; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D012499:Sanitation; D016036:Seroepidemiologic Studies; D014614:Vaccines, Synthetic / Q000276:immunology; D055815:Young Adult
D062705:Adenovirus Vaccines; D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D014614:Vaccines, Synthetic
Adenovirus; Age; China; Human adenovirus type 41; Sanitary condition; Seroprevalence; Vector
J Med Virol. 2012 Sep;84(9):1408-14
22825819
J Gen Virol. 1995 Mar;76 ( Pt 3):481-97
7897343
J Clin Microbiol. 2003 Nov;41(11):5046-52
14605137
Vaccine. 2010 Jan 22;28(4):950-7
19925902
Immunology. 2015 Aug;145(4):476-84
25762305
Virol J. 2012 Nov 23;9:287
23176136
J Virol. 2009 Jan;83(2):748-56
18987146
Lancet. 2008 Nov 29;372(9653):1881-1893
19012954
J Virol Methods. 2011 Aug;175(2):188-96
21601594
J Virol. 2004 Mar;78(6):2666-73
14990686
Microbes Infect. 2006 Jan;8(1):92-104
16126425
J Clin Microbiol. 1987 Sep;25(9):1679-82
3654940
Virology. 2005 Mar 15;333(2):207-14
15721355
Vaccine. 2010 Dec 16;29(2):304-13
21034824
J Virol. 2007 May;81(9):4654-63
17329340
J Clin Virol. 2000 Apr;16(2):145-7
10720819
Microbiol Immunol. 1996;40(2):161-8
8867613
Novartis Found Symp. 2001;238:5-19; discussion 19-25
11444035
Jpn J Microbiol. 1970 Sep;14(5):381-95
4319728
Clin Vaccine Immunol. 2013 Oct;20(10):1508-16
23885027
J Med Virol. 2013 Jun;85(6):1077-84
23588735
J Med Virol. 1983;11(4):333-41
6308143
Clin Vaccine Immunol. 2007 Aug;14(8):1053-5
17596429
Gene Ther. 1998 May;5(5):645-54
9797869
Trends Pharmacol Sci. 2012 Aug;33(8):442-8
22621975
J Clin Microbiol. 1992 Oct;30(10):2733-4
1400977
Vaccine. 2011 Jul 18;29(32):5203-9
21619905
Jpn J Microbiol. 1971 Nov;15(6):499-508
4334551
Front Immunol. 2014 Sep 16;5:446
25278941
Virus Res. 2013 Sep;176(1-2):61-8
23769974
Vaccine. 2007 Mar 1;25(11):2074-84
17250935
Bing Du Xue Bao. 2007 Jul;23(4):258-64
17894226
Arch Virol. 2012 Jul;157(7):1313-21
22527861
Adv Drug Deliv Rev. 2001 Nov 19;52(3):165-76
11718941
J Clin Microbiol. 1995 Jan;33(1):131-6
7699028
Hum Vaccin Immunother. 2014;10(10):2875-84
25483662
J Virol. 2003 Oct;77(20):10780-9
14512528
J Gene Med. 2009 Feb;11(2):128-38
19097028
Vaccine. 2011 May 17;29(22):3837-41
21447314
Arch Virol. 1991;121(1-4):179-97
1759904
Mol Ther. 2001 May;3(5 Pt 1):768-78
11356081
Curr Gene Ther. 2011 Aug;11(4):241-58
21453281